Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Todos Medical Ltd (OP: TOMDF )

0.0127 -0.0005 (-3.79%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,463,446
Open 0.0150
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0132
Today's Range 0.0111 - 0.0150
52wk Range 0.0111 - 0.6440
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
5-day and 30-day dosing regimen for 60-pill bottle allows for both support (5-day dosing) to reduce 3CL protease levels and to maintain (30-day dosing) low 3CL protease levels 
Via Benzinga

Performance

YTD
-75.10%
-75.10%
1 Month
-11.19%
-11.19%
3 Month
-67.44%
-67.44%
6 Month
-71.46%
-71.46%
1 Year
-60.92%
-60.92%

More News

Read More
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Max Strength including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Via NewMediaWire
Exposures Product Safety
Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
Via Benzinga
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction until May 30th, 2022
Via NewMediaWire
Exposures COVID-19
Todos Medical To Present At The Emerging Growth Conference
Via Benzinga
Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics
Via Benzinga
Todos Medical to Present at the Emerging Growth Conference
Via NewMediaWire
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Via NewMediaWire
Todos Medical Reports 2nd Long COVID Case Study And Launches Website For Physicians And Pediatricians To Indicate Interest In Participating In Tollovid® Long COVID Clinical Study
Via Benzinga
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Via NewMediaWire
Exposures COVID-19
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid® by LGC Group
Via Benzinga
UPDATE: Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
Via Benzinga
Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
Via Benzinga
Todos Medical Reports Case Study Of Patient With Long COVID
Via Benzinga
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Via NewMediaWire
New Study Reportedly Calls Into Question Merck's Ivermectin COVID Off Label Use And May Bolster 3CL Protease Inhibitors Such As Tollovid
Via Benzinga
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Via NewMediaWire
Exposures COVID-19 Product Safety
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label
Via Benzinga
Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products
Via Benzinga
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Via Benzinga
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Via NewMediaWire
UPDATE: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
Via NewMediaWire
Exposures COVID-19
Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates
Via NewMediaWire
Exposures COVID-19
Todos Medical Reports Case Study of Patient with Long COVID
Via NewMediaWire
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.